eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2017-03-25 14 1 75 82 10.13005/bbra/2419 22119 article Mayson H. Alkhatib 1 Dunya A. Nori 1 Maryam A. Al-Ghamdi 1 Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia. Sorafenib (SOR), a chemotherapeutic agent, is a multikinase inhibitor that has a cardiotoxic and hematoxic effect which could limit its application in cancer therapy. In the current study, SOR was incorporated into a nanoemulsion (NE) containing flaxseed oil (SOR-NE) and its antitumor effect was examined in Ehrlich ascites carcinoma (EAC)-bearing female Swiss Albino mice. Fifty mice were divided into five groups (n =10). Groups I and II served as untreated mice and untreated EAC-bearing mice, respectively, while groups III-V represented the EAC-mice administered orally with blank NE, SOR dissolved in Cremophor (SOR-Chremo) and SOR- NE, respectively. It has been found that SOR-NE group has lesser counts of white blood cells and decreased levels of cardiac enzymes and relatively normal heart tissue when compared to the SOR-Chremo group. Encapsulating SOR in NE has decreased its cytotoxicity on the heart and blood. https://www.biotech-asia.org/vol14no1/cardiotoxicity-and-hematoxicity-of-sorafenib-loaded-nanoemulsion-in-ehrlich-ascites-carcinoma-bearing-mice/ Chemotherapeutic agents; Cytotoxicity; Cardiac enzymes Flaxseed oil; Nanoparticle;